跳至主要内容
临床试验/NCT01626521
NCT01626521Unknown不适用

Value of Prothrombin Fragment F1+2 in the Diagnosis of Pulmonary Embolism in Patients With Chronic Obstructive Pulmonary Disease (COPD) Exacerbation

Hillel Yaffe Medical Center1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2012年7月最近更新:
适应症

试验速览

阶段
不适用
入组人数
20
试验地点
1
主要终点
Negative Predictive Value of Prothrombin Fragment F1+2

研究概览

简要总结

To access the clinical usefulness of F1+2 in the diagnosis of PE in patients with AECOPD who require hospitalization. Specifically, to determine whether F1+2 may have an additional value in the subgroup of patients with an abnormal D-dimer,to determine whether it may increase the proportion of patients in whom PE can be safely ruled out and to determine the sensitivity, specificity and NPV of F1+2 at various cut-off values.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • COPD exacerbation
  • Able to give informed consent
  • Able to perform spirometry

排除标准

  • Known malignancy
  • Known hypercoagulable state
  • Receiving anticoagulant treatment
  • Pregnancy
  • Renal failure
  • Allergy to iodine

结局指标

主要结局

Negative Predictive Value of Prothrombin Fragment F1+2

时间窗: Six months

Blood test to determine predictive value of Prothrombin Fragment F1+2 in PE diagnosis in hospitalized COPD patients

次要结局

未报告次要终点

研究者

申办方类型
Other Gov
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验